[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100210553":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":19,"locations":24,"responsibleParty":59,"collaborators":19,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":19,"eligibilityCriteria":67,"healthyVolunteers":68,"sex":69,"minAge":70,"maxAge":19,"enrollmentInfo":71,"targetDuration":19,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":82,"whyStopped":19,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":72},{"fullName":5,"class":6},"Novartis","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Everolimus","EXPERIMENTAL","Patients who received everolimus in a Novartis-sponsored, Oncology Clinical Development \\& Medical Affairs (CD\\&MA) study that had reached its study objectives, were not progressing on the current study treatment as defined by the parent protocol and were unable to access everolimus treatment outside of a clinical trial were enrolled.",[13],"Drug: Everolimus",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Everolimus was provided by the investigator in 2.5 mg or 5 mg tablets for daily oral administration.",[9],null,[21],{"name":22,"affiliation":22,"role":23},"Novartis Pharmaceuticals","STUDY_DIRECTOR",[25,38,47,55],{"facility":26,"status":19,"city":27,"state":28,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":19},"Novartis Investigative Site","Matsuyama","Ehime","791-0280","Japan","JP",{"type":33,"coordinates":34},"Point",[35,36],132.76574,33.83916,{"lat":36,"lon":35},{"facility":26,"status":19,"city":39,"state":40,"zip":41,"country":30,"countryCode":31,"cosmosGeoPoint":42,"geoPoint":46,"contacts":19},"Sapporo","Hokkaido","060 8648",{"type":33,"coordinates":43},[44,45],141.35,43.06667,{"lat":45,"lon":44},{"facility":26,"status":19,"city":48,"state":48,"zip":49,"country":30,"countryCode":31,"cosmosGeoPoint":50,"geoPoint":54,"contacts":19},"Osaka","540-0006",{"type":33,"coordinates":51},[52,53],135.50107,34.69379,{"lat":53,"lon":52},{"facility":26,"status":19,"city":56,"state":57,"zip":58,"country":30,"countryCode":31,"cosmosGeoPoint":19,"geoPoint":19,"contacts":19},"Kitaadachi-gun","Saitama","362-0806",{"type":60,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100210553","phase-2-study-to-collect-and-assess-long-term-safety-of-everolimus-in-patients-who-are-on-everolimus-treatment-in-a-novartis-sponsored-study-and-are-benefiting-from-the-treatment-as-judged-by-the-investigator-100210553",true,"NCT02017860","Study to Collect and Assess Long-term Safety of Everolimus in Patients Who Are on Everolimus Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator.","An Open Label, Multi-center Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study and Are Judged by the Investigator to Benefit From Continued Everolimus Treatment.","Inclusion Criteria:\n\n* Patient is currently enrolled in a Novartis-sponsored, CD\\&MA study receiving everolimus or everolimus plus Sandostatin LAR Depot and has fulfilled all their requirements in the parent study\n* Patient is currently benefiting from treatment with everolimus, as determined by the guidelines of the parent protocol.\n\nExclusion Criteria:\n\n* Patient has been permanently discontinued from everolimus study treatment in the parent study.",false,"ALL","18 Years",{"count":72,"type":73},4,"ACTUAL","INTERVENTIONAL",[76],"PHASE2","The purpose of this study was to collect and assess long-term safety of everolimus in patients who were currently receiving everolimus treatment in a Novartis-sponsored, Oncology CD\\&MA study that had reached its study objectives, were not progressing on the current study treatment as defined by the parent protocol, and were unable to access everolimus treatment outside of a clinical study. Parent studies eligible to participate in the roll-over study were decided by Novartis. Investigator initiated trials (IITs) were not included. The primary objective of the parent study must have been reached and the parent study must have been in the process of being completed and reported.",[79],"Neoplasms",[81],"RAD001, everolimus, roll-over","COMPLETED","2020-04-17",{"date":85,"type":73},"2020-04-30",{"date":87,"type":73},"2014-01-16",{"date":89,"type":73},"2019-04-25",{"name":22,"class":6}]